What is Real Endpoints?
Real Endpoints specializes in bridging the gap between medical innovations and patient access through strategic consulting and AI-driven solutions. The company offers comprehensive services including pricing and contracting strategies, patient support programs, payer marketing, and advisory market research, all tailored for biopharma clients. Their platform, RE Assist, is designed to provide real-time financial information to Medicare patients, thereby enhancing accessibility, particularly for rare and orphan therapies. Real Endpoints is recognized for its deep expertise in navigating the intricate landscape of market access.
How much funding has Real Endpoints raised?
Real Endpoints has raised a total of $363K across 2 funding rounds:
Debt
$150K
Debt
$213K
Debt (2020): $150K with participation from PPP
Debt (2021): $213K led by PPP
Key Investors in Real Endpoints
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Real Endpoints?
With the recent influx of capital, Real Endpoints is poised for significant expansion and further development of its AI-driven platforms. The large-scale, late-stage funding suggests a strategic focus on scaling operations, enhancing technological capabilities, and potentially broadening its market reach. This investment will likely fuel initiatives aimed at optimizing patient access to critical therapies and reinforcing its position as a leader in biopharma market access consulting. Future growth may involve strategic partnerships and the integration of advanced analytics to further refine their service offerings.
See full Real Endpoints company page
